By David O'Connell, Director of Scientific and Technical Affairs Rare disease drug development operates in a world where scientific precision, operational discipline, and global coordination matter far more than scale. This article explores how the unique realities of rare diseases - small, geographically dispersed patient populations, highly targeted and often potent molecules, and compressed development timelines - demand a fundamentally different support model.